At NeoGenomics, we understand the importance of precision oncology to support oncologists in delivering personalized patient care. That’s why we have developed both broad pan-cancer and disease-state solutions that give you options for obtaining diagnostic data, therapy guidance, and predictive biomarker insights. With regular updates to keep pace with an evolving cancer landscape, our test menu provides capabilities that align to the latest evidence and guidelines.
As a leader in oncology diagnostics, we provide an extensive range of over 500 tests covering all major testing modalities, including single-gene molecular testing, immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), DNA- and RNA-based next-generation sequencing (NGS), and comprehensive genomic profiling (CGP). Whether it’s for solid tumors or hematologic cancers, we offer advanced tissue-based, liquid biopsy, and heme tests to deliver precise and actionable insights for personalized care.